Oxford Biomedica (LON:OXB) Insider Dame Kay Davies Sells 4,563 Shares of Stock

Oxford Biomedica plc (LON:OXB) insider Dame Kay Davies sold 4,563 shares of Oxford Biomedica stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of GBX 500, for a total transaction of £22,815.

Oxford Biomedica Price Performance

Shares of OXB opened at GBX 536.17 on Friday. The company has a market capitalization of £569.95 million, a P/E ratio of -3.98 and a beta of 1.09. The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48. The firm has a 50 day moving average of GBX 391.12 and a 200 day moving average of GBX 340.65. Oxford Biomedica plc has a twelve month low of GBX 232.50 and a twelve month high of GBX 545.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Oxford Biomedica from GBX 490 to GBX 400 and set a “neutral” rating for the company in a research report on Tuesday, July 15th. Peel Hunt reaffirmed a “buy” rating and issued a GBX 451 target price on shares of Oxford Biomedica in a research report on Friday, August 1st. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of GBX 410.33.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.